JP2003530307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530307A5 JP2003530307A5 JP2001508378A JP2001508378A JP2003530307A5 JP 2003530307 A5 JP2003530307 A5 JP 2003530307A5 JP 2001508378 A JP2001508378 A JP 2001508378A JP 2001508378 A JP2001508378 A JP 2001508378A JP 2003530307 A5 JP2003530307 A5 JP 2003530307A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- adenovirus
- gene
- vaccine
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013598 vector Substances 0.000 description 32
- 241000701161 unidentified adenovirus Species 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 101710177291 Gag polyprotein Proteins 0.000 description 8
- 101710125418 Major capsid protein Proteins 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 229940021704 adenovirus vaccine Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 101150029662 E1 gene Proteins 0.000 description 5
- 230000002950 deficient Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 3
- 101150005585 E3 gene Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 108010057360 Adenovirus E1 Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14263199P | 1999-07-06 | 1999-07-06 | |
| US60/142,631 | 1999-07-06 | ||
| US14898199P | 1999-08-13 | 1999-08-13 | |
| US60/148,981 | 1999-08-13 | ||
| PCT/US2000/018332 WO2001002607A1 (en) | 1999-07-06 | 2000-07-03 | Adenovirus carrying gag gene hiv vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530307A JP2003530307A (ja) | 2003-10-14 |
| JP2003530307A5 true JP2003530307A5 (enExample) | 2006-12-07 |
Family
ID=26840267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001508378A Withdrawn JP2003530307A (ja) | 1999-07-06 | 2000-07-03 | ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6787351B2 (enExample) |
| EP (1) | EP1200622A4 (enExample) |
| JP (1) | JP2003530307A (enExample) |
| CA (1) | CA2378539A1 (enExample) |
| WO (1) | WO2001002607A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020088014A1 (en) * | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| WO2000039304A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| CA2360347C (en) | 1998-12-31 | 2013-05-07 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| EP2388015A1 (en) | 2000-03-02 | 2011-11-23 | Emory University | DNA expression vectors and methods of use |
| US20020155127A1 (en) * | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
| US7754201B2 (en) * | 2000-06-02 | 2010-07-13 | GenPhar, Inc | Method of vaccination through serotype rotation |
| AU2001280006B2 (en) * | 2000-07-14 | 2006-07-13 | University Of Saskatchewan | Adenovirus vectors comprising introns |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| US6893840B2 (en) | 2000-10-13 | 2005-05-17 | Chiron Corporation | Cytomegalovirus Intron A fragments |
| DE60234018D1 (de) | 2001-03-08 | 2009-11-26 | Univ Emory | Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene |
| US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| AU2002337840B2 (en) | 2001-10-11 | 2007-08-09 | Msd Italia S.R.L. | Hepatitis C virus vaccine |
| SG165153A1 (en) | 2001-11-21 | 2010-10-28 | Univ Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| AU2002347317B2 (en) | 2001-11-30 | 2008-06-26 | Isis Innovation Limited | Vaccine |
| AU2003220237A1 (en) * | 2002-03-13 | 2003-09-29 | Merck & Co., Inc. | Method of inducing an enhanced immune response against hiv |
| EP1492891B1 (en) | 2002-03-29 | 2008-02-20 | Merck & Co., Inc. | Methods of virus production |
| ATE494362T1 (de) | 2002-05-14 | 2011-01-15 | Merck Sharp & Dohme | Verfahren zur reinigung von adenovirus |
| AU2003288273A1 (en) | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| CA2507915C (en) | 2002-12-17 | 2013-07-02 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| JP2007515386A (ja) * | 2003-09-18 | 2007-06-14 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖ感染個体の治療用免疫化 |
| JP2007532656A (ja) * | 2004-04-12 | 2007-11-15 | アメリカ合衆国 | アデノウイルスベクターを用いて免疫応答を誘導するための方法 |
| KR101253363B1 (ko) | 2004-10-13 | 2013-04-15 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 개선된 아데노바이러스 벡터 및 그것의 용도 |
| WO2007050095A2 (en) | 2004-11-19 | 2007-05-03 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| US20090181424A1 (en) * | 2005-04-22 | 2009-07-16 | Fernando Albericio | Mammalian Expression Vector Comprising the MCMV Promoter and First Intron of HCMV Major Immediate Early Gene |
| JP2009520790A (ja) * | 2005-12-21 | 2009-05-28 | グラクソ グループ リミテッド | 免疫応答を惹起する方法 |
| AU2006345511B2 (en) * | 2006-05-25 | 2013-03-21 | Institute For Advanced Study | Methods for identifying sequence motifs, and applications thereof |
| AU2007345319B2 (en) | 2006-07-13 | 2012-09-06 | Institute For Advanced Study | Viral inhibitory nucleotide sequences and vaccines |
| US8926993B2 (en) * | 2006-07-17 | 2015-01-06 | Aduro Biotech | Methods and compositions using Listeria for enhancing immunogenicity by prime boost |
| GB0706914D0 (en) | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
| WO2009026183A1 (en) * | 2007-08-17 | 2009-02-26 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Use of chimeric hiv/siv gag proteins to optimize vaccine-induced t cell responses against hiv gag |
| CN102123724B (zh) | 2008-06-19 | 2018-05-01 | 变异生技公司 | 治疗流行性感冒的组合物和方法 |
| EP2213299B1 (fr) | 2009-01-29 | 2015-09-09 | Michel Vandevelde | Composition vaccinale à base de virus exhibant une protéine à motif(s) en doigt de zinc, son procédé de préparation et son utilisation |
| BR112012000826B1 (pt) | 2009-07-06 | 2022-07-26 | Variation Biotechnologies Inc | Método para a preparação de vesículas |
| CA2803282C (en) | 2009-07-06 | 2018-05-01 | David E. Anderson | Methods for preparing vesicles and formulations produced therefrom |
| BRPI0914507A2 (pt) * | 2009-12-23 | 2012-04-10 | Fundacao Oswaldo Cruz | vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela |
| MX342138B (es) | 2010-07-06 | 2016-09-14 | Variation Biotechnologies Inc | Composiciones y metodos para el tratamiento de influenza. |
| WO2012097346A1 (en) | 2011-01-13 | 2012-07-19 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
| US10183069B2 (en) * | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
| AP2013007166A0 (en) | 2011-04-06 | 2013-10-31 | Univ Paris Descartes Inst De Rech Pour Le Dev Ird | Pharmaceutical compositions for preventing and/or treating an HIV disease in humans |
| CN104302323A (zh) | 2012-01-12 | 2015-01-21 | 变异生物技术公司 | 用于治疗病毒感染的组合物和方法 |
| AU2013213345A1 (en) | 2012-01-27 | 2014-08-28 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| DK2825640T3 (en) | 2012-03-12 | 2016-08-01 | Crucell Holland Bv | BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END |
| KR101466875B1 (ko) * | 2012-05-11 | 2014-12-03 | 가톨릭대학교 산학협력단 | 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료 |
| KR101466874B1 (ko) * | 2012-05-11 | 2014-12-03 | 가톨릭대학교 산학협력단 | 자가면역 질환의 예방과 치료를 위한 ｉｌ-６ 수용체에 대한 항체를 발현하는 미니서클 |
| US10106781B2 (en) | 2012-11-16 | 2018-10-23 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
| SI3271729T1 (sl) | 2015-03-18 | 2021-04-30 | Janssen Vaccines & Prevention B.V. | Testi za rekombinantne ekspresijske sisteme |
| WO2016166088A1 (en) | 2015-04-14 | 2016-10-20 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| MX393584B (es) | 2016-06-20 | 2025-03-21 | Janssen Vaccines & Prevention Bv | Promotor bidireccional potente y equilibrado. |
| WO2019086466A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| AU2018359492B2 (en) | 2017-10-31 | 2023-12-14 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| SG11202003398SA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus vectors and uses thereof |
| SG11202003290RA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus and uses thereof |
| WO2019118480A1 (en) | 2017-12-11 | 2019-06-20 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
| WO2020243485A1 (en) | 2019-05-29 | 2020-12-03 | Massachusetts Institute Of Technology | Hiv-1 specific immunogen compositions and methods of use |
| MX2022004028A (es) | 2019-10-03 | 2022-05-02 | Janssen Vaccines & Prevention Bv | Vectores de adenovirus y usos de los mismos. |
| US11571672B2 (en) | 2019-11-25 | 2023-02-07 | Saudi Arabian Oil Company | Method of providing catalysts for a fluidized bed reactor |
| CN111949888B (zh) * | 2020-09-02 | 2023-10-10 | 度小满科技(北京)有限公司 | 一种数据推荐方法及装置 |
| WO2025242657A1 (en) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Lipopeptide building blocks and aggregates |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| CA2003383A1 (en) * | 1988-11-23 | 1990-05-23 | Sushil G. Devare | Synthetic dna derived recombinant hiv antigens |
| PT586076E (pt) | 1992-08-07 | 2003-11-28 | Wyeth Corp | Vacinas de adenovirus recombinantes |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| DK0638316T3 (da) | 1993-08-11 | 2003-09-22 | Wyeth Corp | Rekombinante adenovirusvacciner |
| EP0707071B1 (en) | 1994-08-16 | 2003-07-30 | Crucell Holland B.V. | Recombinant vectors derived from adenovirus for use in gene therapy |
| AU4647296A (en) | 1994-12-30 | 1996-07-24 | Chiron Corporation | Combination gene delivery vehicles |
| AU6261696A (en) | 1995-06-05 | 1996-12-24 | Trustees Of The University Of Pennsylvania, The | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| WO1996039178A1 (en) | 1995-06-05 | 1996-12-12 | The Wistar Institute Of Anatomy And Biology | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| US5994128A (en) | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US5672508A (en) * | 1996-01-23 | 1997-09-30 | Mitotix, Inc. | Inhibitors of cell-cycle progression, and uses related thereto |
| CN1216064A (zh) | 1996-02-22 | 1999-05-05 | 麦克公司 | 合成的hiv基因 |
| AU2678797A (en) | 1996-04-22 | 1997-11-12 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Heterologous boosting immunizations |
| AU728422B2 (en) | 1996-06-21 | 2001-01-11 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
| EP0969862B1 (en) | 1997-02-07 | 2006-10-18 | Merck & Co., Inc. | Synthetic hiv gag genes |
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| WO2001002067A1 (es) | 1999-06-30 | 2001-01-11 | Javier Garrigues Mateo | Sistema de deteccion del fuera de juego |
| GB9922361D0 (en) | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| JP2003516741A (ja) | 1999-12-17 | 2003-05-20 | メルク エンド カムパニー インコーポレーテッド | コドン最適化ＨＩＶ−１Ｎｅｆ及び修飾ＨＩＶ−１Ｎｅｆを発現するポリヌクレオチドワクチン |
| WO2001045748A1 (en) | 1999-12-22 | 2001-06-28 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
-
2000
- 2000-07-03 EP EP00945133A patent/EP1200622A4/en not_active Withdrawn
- 2000-07-03 CA CA002378539A patent/CA2378539A1/en not_active Abandoned
- 2000-07-03 JP JP2001508378A patent/JP2003530307A/ja not_active Withdrawn
- 2000-07-03 WO PCT/US2000/018332 patent/WO2001002607A1/en not_active Ceased
-
2001
- 2001-03-27 US US09/818,443 patent/US6787351B2/en not_active Expired - Fee Related
-
2003
- 2003-06-13 US US10/461,030 patent/US20030228329A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003530307A5 (enExample) | ||
| JP7053728B2 (ja) | 組換えアデノウイルスおよびその使用 | |
| US11104916B2 (en) | Compositions and methods for alphavirus vaccination | |
| US12285481B2 (en) | Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein | |
| US20220062409A1 (en) | Heterologous prime boost vaccine compositions and methods | |
| JP2004508064A5 (enExample) | ||
| TWI828168B (zh) | 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途 | |
| JP2002533124A5 (enExample) | ||
| EP1825863A1 (en) | Recombinant porcine adenovirus vector | |
| JP2005505286A5 (enExample) | ||
| KR20230050328A (ko) | Hbv에 대한 rna 레플리콘 백신 | |
| JP2004501650A5 (enExample) | ||
| CN111363726A (zh) | 表达干扰素的溶瘤病毒及其应用 | |
| JP2004501646A5 (enExample) | ||
| FR2712602A1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| KR20200100745A (ko) | B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물 | |
| CN100471957C (zh) | 用于免疫治疗的腺病毒载体 | |
| CA2461579A1 (en) | Porcine adenovirus e1 region | |
| Chengalvala et al. | Adenovirus vectors for gene expression | |
| JP2002528519A (ja) | 抗腫瘍効果を有する、抗原性タンパク質をコードしているｄｎａを含む医薬組成物 | |
| KR100686356B1 (ko) | 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제 | |
| JP2008521384A (ja) | コロナウィルス様粒子をコードする発現ベクター | |
| EP1549751A2 (fr) | Vecteurs adenoviraux recombinants et leurs applications | |
| Pergolizzi et al. | Protective immunity against α-cobratoxin following a single administration of a genetic vaccine encoding a non-toxic cobratoxin variant | |
| US11352643B2 (en) | Enhanced promoter |